Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR): A multicenter, randomized, open-label, phase 2/3 trial.
Yuichiro Tsukada(National Cancer Center Hospital East), Masaaki Ito(National Cancer Centre Japan), Yuji Nishizawa(National Cancer Center Hospital East), Toshihiro Misumi(Yokohama City University), Keiji Koda(Teikyo University Chiba Medical Center), Fumihiko Fujita(Japan Society of Laparoscopic Colorectal Surgery), Hideaki Bando(Aichi Cancer Center), Yoshiyuki Kawashima(Saitama Prefecture), Takayuki Yoshino(University of Tsukuba), Akihiko Murata(Tottori University), Eiji Shinto(Self-Defense Forces Central Hospital), Yoshikazu Koide(Fujita Health University Hospital), Norio Saitô(National Cancer Center Hospital East), Motoko Suzuki(St. Marianna University School of Medicine), Masayuki Ohue(Hyogo Medical University)
Cited by 1
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k